BioCentury

7:00 AM GMT, Apr 21, 2008
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 4/18 cls
Affymetrix (NASDAQ:AFFX) Leerink John Sullivan Downgrade Market perform (from market outperform) $11.16 -32%
Sullivan lowered his target to $12-$13 from $19-$22 and lowered his FY08 and FY09 revenue estimates to $394.8M from $422.7M and to $420.9M from $464.4M, respectively. He also lowered his FY08 and FY09 EPS estimates to $0.43 from $0.54 and to $0.63 from $0.73, respectively. He downgraded and lowered his estimates after Affymetrix reduced its FY08 revenue estimate to $490-$510M from $505-$525M.
AMAG Pharma (NASDAQ: AMAG) Summer Street Carol Werther Upgrade Buy (from neutral) $36.40 -3%
Werther set a $62 target. She expects ferumoxytol, under review by FDA to treat iron deficiency anemia in patients with chronic kidney disease (CKD), to receive approval in October and to reach peak sales of $340M

Read the full 1384 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.